Peter Moldt
Director/Board Member at Cardeas Pharma Corp.
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Scott A. Byrd | M | 54 |
Outpost Medicine, Inc.
Outpost Medicine, Inc. Pharmaceuticals: MajorHealth Technology Outpost Medicine LLC develops therapeutics for the treatment of urologic and gynecologic disorders. The company was founded by David Socks and Tachi Yamada in 2016 and is headquartered in Lexington, MA. | 7 years |
Heath Lukatch | M | 56 |
Viewpoint Therapeutics, Inc.
Viewpoint Therapeutics, Inc. BiotechnologyHealth Technology Viewpoint Therapeutics, Inc. operates as a biotechnology company. It prevents and treats cataracts and presbyopia, and protein misfolding. The company was founded by Leah Makley in July of 2014 and is headquartered in San Francisco, CA.
Novo Ventures (US), Inc.
Novo Ventures (US), Inc. Investment ManagersFinance Novo Ventures (US), Inc. is a venture capital firm located in San Francisco. The firm is a subsidiary of Novo A/S and their ultimate parent is Novo Nordisk Fonden. | 16 years |
Leah Makley | M | - |
Viewpoint Therapeutics, Inc.
Viewpoint Therapeutics, Inc. BiotechnologyHealth Technology Viewpoint Therapeutics, Inc. operates as a biotechnology company. It prevents and treats cataracts and presbyopia, and protein misfolding. The company was founded by Leah Makley in July of 2014 and is headquartered in San Francisco, CA. | 10 years |
Edward Hurwitz | M | 60 |
Viewpoint Therapeutics, Inc.
Viewpoint Therapeutics, Inc. BiotechnologyHealth Technology Viewpoint Therapeutics, Inc. operates as a biotechnology company. It prevents and treats cataracts and presbyopia, and protein misfolding. The company was founded by Leah Makley in July of 2014 and is headquartered in San Francisco, CA. | 10 years |
Mark W. Surber | M | - |
Avalyn Pharma, Inc.
Avalyn Pharma, Inc. Pharmaceuticals: MajorHealth Technology Avalyn Pharma, Inc. manufactures pharmaceutical products. It develops improved therapies for the treatment of idiopathic pulmonary fibrosis (IPF) and other severe respiratory diseases. The company was founded by Richard Glenn Vincent and Mark W. Surber in 2011 and is headquartered in Seattle, WA. | 13 years |
Richard Miller | M | 73 | 7 years | |
Scott Morrison | M | 66 | 9 years | |
Lyn Baranowski | F | - |
Avalyn Pharma, Inc.
Avalyn Pharma, Inc. Pharmaceuticals: MajorHealth Technology Avalyn Pharma, Inc. manufactures pharmaceutical products. It develops improved therapies for the treatment of idiopathic pulmonary fibrosis (IPF) and other severe respiratory diseases. The company was founded by Richard Glenn Vincent and Mark W. Surber in 2011 and is headquartered in Seattle, WA. | 2 years |
Mahendra Shah | M | 79 | 8 years | |
Tiba Aynechi | M | 48 |
Novo Ventures (US), Inc.
Novo Ventures (US), Inc. Investment ManagersFinance Novo Ventures (US), Inc. is a venture capital firm located in San Francisco. The firm is a subsidiary of Novo A/S and their ultimate parent is Novo Nordisk Fonden.
Avalyn Pharma, Inc.
Avalyn Pharma, Inc. Pharmaceuticals: MajorHealth Technology Avalyn Pharma, Inc. manufactures pharmaceutical products. It develops improved therapies for the treatment of idiopathic pulmonary fibrosis (IPF) and other severe respiratory diseases. The company was founded by Richard Glenn Vincent and Mark W. Surber in 2011 and is headquartered in Seattle, WA. | 14 years |
Linda Grais | M | 68 | 5 years | |
Scott A. Beardsley | M | 56 |
Novo Ventures (US), Inc.
Novo Ventures (US), Inc. Investment ManagersFinance Novo Ventures (US), Inc. is a venture capital firm located in San Francisco. The firm is a subsidiary of Novo A/S and their ultimate parent is Novo Nordisk Fonden. | 12 years |
Sarah Nemec | F | 48 | 4 years | |
Grant Yonehiro | M | 60 | 8 years | |
Jonathan Leff | M | 66 |
Avalyn Pharma, Inc.
Avalyn Pharma, Inc. Pharmaceuticals: MajorHealth Technology Avalyn Pharma, Inc. manufactures pharmaceutical products. It develops improved therapies for the treatment of idiopathic pulmonary fibrosis (IPF) and other severe respiratory diseases. The company was founded by Richard Glenn Vincent and Mark W. Surber in 2011 and is headquartered in Seattle, WA. | 7 years |
James Healy | M | 58 | 3 years | |
Ian Clark | M | 62 | 7 years | |
Kathy LaPorte | F | 62 | 4 years | |
Ming Cheah | M | - |
Avalyn Pharma, Inc.
Avalyn Pharma, Inc. Pharmaceuticals: MajorHealth Technology Avalyn Pharma, Inc. manufactures pharmaceutical products. It develops improved therapies for the treatment of idiopathic pulmonary fibrosis (IPF) and other severe respiratory diseases. The company was founded by Richard Glenn Vincent and Mark W. Surber in 2011 and is headquartered in Seattle, WA. | 2 years |
Gabriel Luciano | M | - | 6 years | |
Shawnalea Frazier | F | - |
Novo Ventures (US), Inc.
Novo Ventures (US), Inc. Investment ManagersFinance Novo Ventures (US), Inc. is a venture capital firm located in San Francisco. The firm is a subsidiary of Novo A/S and their ultimate parent is Novo Nordisk Fonden. | 9 years |
Marianne Mann | F | - |
Cardeas Pharma Corp.
Cardeas Pharma Corp. Pharmaceuticals: MajorHealth Technology Cardeas Pharma Corp. develops drugs for the prevention of ventilator associated pneumonia. It offers a novel antibiotic formulation of two drugs with synergistic activity against relevant, resistant Gram-negative bacilli, including pseudomonas aeruginosa, acinetobacter baumannii, and carbapenem-resistant Enterobacteriaceae. The company was founded by Alan Bruce Montgomery on November 23, 2011 and is headquartered in Seattle, WA. | - |
Raymond Camahort | M | 45 |
Novo Ventures (US), Inc.
Novo Ventures (US), Inc. Investment ManagersFinance Novo Ventures (US), Inc. is a venture capital firm located in San Francisco. The firm is a subsidiary of Novo A/S and their ultimate parent is Novo Nordisk Fonden. | 9 years |
Wesley Burwell | M | - | 3 years | |
Kenneth Harrison | M | 44 |
Novo Ventures (US), Inc.
Novo Ventures (US), Inc. Investment ManagersFinance Novo Ventures (US), Inc. is a venture capital firm located in San Francisco. The firm is a subsidiary of Novo A/S and their ultimate parent is Novo Nordisk Fonden. | 9 years |
Melissa Rhodes | M | - |
Avalyn Pharma, Inc.
Avalyn Pharma, Inc. Pharmaceuticals: MajorHealth Technology Avalyn Pharma, Inc. manufactures pharmaceutical products. It develops improved therapies for the treatment of idiopathic pulmonary fibrosis (IPF) and other severe respiratory diseases. The company was founded by Richard Glenn Vincent and Mark W. Surber in 2011 and is headquartered in Seattle, WA. | 1 years |
John Tomaro | M | - | 4 years | |
Suresh Mahabhashyam | M | - | 5 years | |
Eric M. Snyder | M | - |
Novo Ventures (US), Inc.
Novo Ventures (US), Inc. Investment ManagersFinance Novo Ventures (US), Inc. is a venture capital firm located in San Francisco. The firm is a subsidiary of Novo A/S and their ultimate parent is Novo Nordisk Fonden. | 6 years |
Tony Scullion | M | - |
Cardeas Pharma Corp.
Cardeas Pharma Corp. Pharmaceuticals: MajorHealth Technology Cardeas Pharma Corp. develops drugs for the prevention of ventilator associated pneumonia. It offers a novel antibiotic formulation of two drugs with synergistic activity against relevant, resistant Gram-negative bacilli, including pseudomonas aeruginosa, acinetobacter baumannii, and carbapenem-resistant Enterobacteriaceae. The company was founded by Alan Bruce Montgomery on November 23, 2011 and is headquartered in Seattle, WA. | - |
Chen Yu | M | - |
Outpost Medicine, Inc.
Outpost Medicine, Inc. Pharmaceuticals: MajorHealth Technology Outpost Medicine LLC develops therapeutics for the treatment of urologic and gynecologic disorders. The company was founded by David Socks and Tachi Yamada in 2016 and is headquartered in Lexington, MA. | - |
Heather Elizabeth Preston | M | 58 |
Avalyn Pharma, Inc.
Avalyn Pharma, Inc. Pharmaceuticals: MajorHealth Technology Avalyn Pharma, Inc. manufactures pharmaceutical products. It develops improved therapies for the treatment of idiopathic pulmonary fibrosis (IPF) and other severe respiratory diseases. The company was founded by Richard Glenn Vincent and Mark W. Surber in 2011 and is headquartered in Seattle, WA. | 7 years |
Anna Fan | M | - |
Novo Ventures (US), Inc.
Novo Ventures (US), Inc. Investment ManagersFinance Novo Ventures (US), Inc. is a venture capital firm located in San Francisco. The firm is a subsidiary of Novo A/S and their ultimate parent is Novo Nordisk Fonden. | 7 years |
Nilesh Kumar | M | 47 |
Novo Ventures (US), Inc.
Novo Ventures (US), Inc. Investment ManagersFinance Novo Ventures (US), Inc. is a venture capital firm located in San Francisco. The firm is a subsidiary of Novo A/S and their ultimate parent is Novo Nordisk Fonden. | 9 years |
Aaron Davidson | M | 55 |
Cardeas Pharma Corp.
Cardeas Pharma Corp. Pharmaceuticals: MajorHealth Technology Cardeas Pharma Corp. develops drugs for the prevention of ventilator associated pneumonia. It offers a novel antibiotic formulation of two drugs with synergistic activity against relevant, resistant Gram-negative bacilli, including pseudomonas aeruginosa, acinetobacter baumannii, and carbapenem-resistant Enterobacteriaceae. The company was founded by Alan Bruce Montgomery on November 23, 2011 and is headquartered in Seattle, WA. | - |
Daniel J. Estes | M | 43 |
Outpost Medicine, Inc.
Outpost Medicine, Inc. Pharmaceuticals: MajorHealth Technology Outpost Medicine LLC develops therapeutics for the treatment of urologic and gynecologic disorders. The company was founded by David Socks and Tachi Yamada in 2016 and is headquartered in Lexington, MA. | 8 years |
Søren Møller | M | 56 |
Novo Holdings AS (Denmark)
Novo Holdings AS (Denmark) Financial ConglomeratesFinance Novo Holding A/S provides financial investments and manages the Novo Nordisk Foundation?s assets. It offers seed and venture capital to development stage companies and takes ownership positions in companies within life science and biotechnology. The company was founded on September 8, 1999 and is headquartered in Hellerup, Denmark. | 13 years |
Sofia Ioannidou | M | 45 |
Avalyn Pharma, Inc.
Avalyn Pharma, Inc. Pharmaceuticals: MajorHealth Technology Avalyn Pharma, Inc. manufactures pharmaceutical products. It develops improved therapies for the treatment of idiopathic pulmonary fibrosis (IPF) and other severe respiratory diseases. The company was founded by Richard Glenn Vincent and Mark W. Surber in 2011 and is headquartered in Seattle, WA. | - |
Niall O'Donnell | M | 51 |
Avalyn Pharma, Inc.
Avalyn Pharma, Inc. Pharmaceuticals: MajorHealth Technology Avalyn Pharma, Inc. manufactures pharmaceutical products. It develops improved therapies for the treatment of idiopathic pulmonary fibrosis (IPF) and other severe respiratory diseases. The company was founded by Richard Glenn Vincent and Mark W. Surber in 2011 and is headquartered in Seattle, WA. | 7 years |
William Quinn | M | 53 | 4 years | |
Ketan Patel | M | 49 |
Avalyn Pharma, Inc.
Avalyn Pharma, Inc. Pharmaceuticals: MajorHealth Technology Avalyn Pharma, Inc. manufactures pharmaceutical products. It develops improved therapies for the treatment of idiopathic pulmonary fibrosis (IPF) and other severe respiratory diseases. The company was founded by Richard Glenn Vincent and Mark W. Surber in 2011 and is headquartered in Seattle, WA. | 7 years |
Karen Ho Hong | M | 52 |
Novo Ventures (US), Inc.
Novo Ventures (US), Inc. Investment ManagersFinance Novo Ventures (US), Inc. is a venture capital firm located in San Francisco. The firm is a subsidiary of Novo A/S and their ultimate parent is Novo Nordisk Fonden. | 5 years |
Kevin Kinsella | M | 78 |
Cardeas Pharma Corp.
Cardeas Pharma Corp. Pharmaceuticals: MajorHealth Technology Cardeas Pharma Corp. develops drugs for the prevention of ventilator associated pneumonia. It offers a novel antibiotic formulation of two drugs with synergistic activity against relevant, resistant Gram-negative bacilli, including pseudomonas aeruginosa, acinetobacter baumannii, and carbapenem-resistant Enterobacteriaceae. The company was founded by Alan Bruce Montgomery on November 23, 2011 and is headquartered in Seattle, WA. | - |
Emmett Cunningham | M | 63 |
Viewpoint Therapeutics, Inc.
Viewpoint Therapeutics, Inc. BiotechnologyHealth Technology Viewpoint Therapeutics, Inc. operates as a biotechnology company. It prevents and treats cataracts and presbyopia, and protein misfolding. The company was founded by Leah Makley in July of 2014 and is headquartered in San Francisco, CA. | - |
Terry Gould | M | 67 |
Outpost Medicine, Inc.
Outpost Medicine, Inc. Pharmaceuticals: MajorHealth Technology Outpost Medicine LLC develops therapeutics for the treatment of urologic and gynecologic disorders. The company was founded by David Socks and Tachi Yamada in 2016 and is headquartered in Lexington, MA. | 8 years |
Robert T. deGavre | M | - |
Cardeas Pharma Corp.
Cardeas Pharma Corp. Pharmaceuticals: MajorHealth Technology Cardeas Pharma Corp. develops drugs for the prevention of ventilator associated pneumonia. It offers a novel antibiotic formulation of two drugs with synergistic activity against relevant, resistant Gram-negative bacilli, including pseudomonas aeruginosa, acinetobacter baumannii, and carbapenem-resistant Enterobacteriaceae. The company was founded by Alan Bruce Montgomery on November 23, 2011 and is headquartered in Seattle, WA. | - |
David Malek | M | 47 |
Avalyn Pharma, Inc.
Avalyn Pharma, Inc. Pharmaceuticals: MajorHealth Technology Avalyn Pharma, Inc. manufactures pharmaceutical products. It develops improved therapies for the treatment of idiopathic pulmonary fibrosis (IPF) and other severe respiratory diseases. The company was founded by Richard Glenn Vincent and Mark W. Surber in 2011 and is headquartered in Seattle, WA. | - |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Steve Krognes | M | 56 | 5 years | |
Jason V. Coloma | M | - | - | |
Ashish Khanna | M | 52 | 3 years | |
David Dornan | M | 46 | 3 years | |
Randall Schatzman | M | 69 | 5 years | |
Michael Shalmi | M | 59 |
Novo Holdings AS (Denmark)
Novo Holdings AS (Denmark) Financial ConglomeratesFinance Novo Holding A/S provides financial investments and manages the Novo Nordisk Foundation?s assets. It offers seed and venture capital to development stage companies and takes ownership positions in companies within life science and biotechnology. The company was founded on September 8, 1999 and is headquartered in Hellerup, Denmark. | 7 years |
Nanna Liebach Lüneborg | M | 49 |
Novo Holdings AS (Denmark)
Novo Holdings AS (Denmark) Financial ConglomeratesFinance Novo Holding A/S provides financial investments and manages the Novo Nordisk Foundation?s assets. It offers seed and venture capital to development stage companies and takes ownership positions in companies within life science and biotechnology. The company was founded on September 8, 1999 and is headquartered in Hellerup, Denmark. | 9 years |
Debra Horen | F | - | - | |
Edith Perez | M | 67 | 4 years | |
Mehrdad Mobasher | M | 51 | - | |
Jason Pitts | M | 38 | 1 years | |
Daniel W. Hunt | M | 62 | - | |
Ginna Laport | M | 60 | 3 years | |
Laurie C. Torres | F | 61 | - | |
Cory Freedland | M | 48 |
Novo Ventures (US), Inc.
Novo Ventures (US), Inc. Investment ManagersFinance Novo Ventures (US), Inc. is a venture capital firm located in San Francisco. The firm is a subsidiary of Novo A/S and their ultimate parent is Novo Nordisk Fonden. | - |
Peter Bisgaard | M | 50 |
Novo Holdings AS (Denmark)
Novo Holdings AS (Denmark) Financial ConglomeratesFinance Novo Holding A/S provides financial investments and manages the Novo Nordisk Foundation?s assets. It offers seed and venture capital to development stage companies and takes ownership positions in companies within life science and biotechnology. The company was founded on September 8, 1999 and is headquartered in Hellerup, Denmark. | 8 years |
Bobby G. Soni | M | 53 |
Novo Holdings AS (Denmark)
Novo Holdings AS (Denmark) Financial ConglomeratesFinance Novo Holding A/S provides financial investments and manages the Novo Nordisk Foundation?s assets. It offers seed and venture capital to development stage companies and takes ownership positions in companies within life science and biotechnology. The company was founded on September 8, 1999 and is headquartered in Hellerup, Denmark. | - |
Eric N. Shiozaki | M | - |
Novo Ventures (US), Inc.
Novo Ventures (US), Inc. Investment ManagersFinance Novo Ventures (US), Inc. is a venture capital firm located in San Francisco. The firm is a subsidiary of Novo A/S and their ultimate parent is Novo Nordisk Fonden. | 7 years |
Hans Werdelin | M | 85 |
Novo Holdings AS (Denmark)
Novo Holdings AS (Denmark) Financial ConglomeratesFinance Novo Holding A/S provides financial investments and manages the Novo Nordisk Foundation?s assets. It offers seed and venture capital to development stage companies and takes ownership positions in companies within life science and biotechnology. The company was founded on September 8, 1999 and is headquartered in Hellerup, Denmark. | - |
Jeppe Fonager Christiansen | M | 64 |
Novo Holdings AS (Denmark)
Novo Holdings AS (Denmark) Financial ConglomeratesFinance Novo Holding A/S provides financial investments and manages the Novo Nordisk Foundation?s assets. It offers seed and venture capital to development stage companies and takes ownership positions in companies within life science and biotechnology. The company was founded on September 8, 1999 and is headquartered in Hellerup, Denmark. | - |
Søren Schifter | M | - |
Novo Ventures 1 A/S
Novo Ventures 1 A/S Investment ManagersFinance Novo Ventures (Novo Ventures) is a venture capital operating division of Novo Nordisk Fonden. It engages in investment activities. The firm was established in 1999, and is headquartered in Hellerup, Denmark. | 8 years |
Jack Nielsen | M | 60 |
Novo Ventures (US), Inc.
Novo Ventures (US), Inc. Investment ManagersFinance Novo Ventures (US), Inc. is a venture capital firm located in San Francisco. The firm is a subsidiary of Novo A/S and their ultimate parent is Novo Nordisk Fonden. | 6 years |
Helle Busck Fensvig | F | 59 |
Curalogic AS
Curalogic AS Pharmaceuticals: MajorHealth Technology The Group's principal activities is the development of pharmaceuticals for the treatment of allergy. | 4 years |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 61 | 87.14% |
Denmark | 9 | 12.86% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Peter Moldt
- Personal Network